DK0417725T3 - Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler. - Google Patents

Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler.

Info

Publication number: DK0417725T3
Authority: DK; Denmark
Prior art keywords: bile acid; substance; acid residue; acid derivatives; absorbed
Prior art date: 1989-09-14

Application number

DK90117470.6T

Other languages

English (en)

Inventor

Werner Dr Kramer

G Wess

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-14

Filing date

1990-09-11

Publication date

1997-11-03

1990-09-11 Application filed by Hoechst Ag filed Critical Hoechst Ag

1997-11-03 Application granted granted Critical

1997-11-03 Publication of DK0417725T3 publication Critical patent/DK0417725T3/da

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 5
239000003814 drug Substances 0.000 title abstract 3
239000013543 active substance Substances 0.000 abstract 3
210000004185 liver Anatomy 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
206010016654 Fibrosis Diseases 0.000 abstract 1
230000009102 absorption Effects 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
125000003158 alcohol group Chemical group 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000001315 anti-hyperlipaemic effect Effects 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000003443 antiviral agent Substances 0.000 abstract 1
239000003613 bile acid Substances 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
230000036772 blood pressure Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000007882 cirrhosis Effects 0.000 abstract 1
208000019425 cirrhosis of liver Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000010235 enterohepatic circulation Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
230000009103 reabsorption Effects 0.000 abstract 1
239000002461 renin inhibitor Substances 0.000 abstract 1
229940086526 renin-inhibitors Drugs 0.000 abstract 1
150000003839 salts Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Lubricants (AREA)
Vessels, Lead-In Wires, Accessory Apparatuses For Cathode-Ray Tubes (AREA)
Control Of Heat Treatment Processes (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK90117470.6T 1989-09-14 1990-09-11 Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler. DK0417725T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3930696A DE3930696A1 (de)	1989-09-14	1989-09-14	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
DK0417725T3 true DK0417725T3 (da)	1997-11-03

Family

ID=6389405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90117470.6T DK0417725T3 (da)	1989-09-14	1990-09-11	Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler.

Country Status (21)

Country	Link
US (3)	US5462933A (da)
EP (1)	EP0417725B1 (da)
JP (3)	JP2568306B2 (da)
KR (1)	KR0166962B1 (da)
AT (1)	ATE152117T1 (da)
AU (1)	AU637822B2 (da)
CA (1)	CA2025294C (da)
CY (1)	CY2112B1 (da)
DE (2)	DE3930696A1 (da)
DK (1)	DK0417725T3 (da)
ES (1)	ES2100858T3 (da)
FI (1)	FI105155B (da)
GR (1)	GR3024095T3 (da)
HU (1)	HU213395B (da)
IE (1)	IE903329A1 (da)
IL (1)	IL95668A (da)
NO (1)	NO303450B1 (da)
NZ (1)	NZ235285A (da)
PT (1)	PT95299B (da)
TW (1)	TW199097B (da)
ZA (1)	ZA907300B (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3930696A1 (de) *	1989-09-14	1991-03-28	Hoechst Ag	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
ES2053333T3 (es) *	1990-07-26	1994-07-16	Searle & Co	Sistema polimerico para la administracion de farmacos.
US5693769A (en) *	1991-12-13	1997-12-02	Transcell Technologies, Inc.	Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) *	1991-12-13	1998-08-18	Trustees Of Princeton University	Compositions and methods for cell transformation
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
EP0548793A3 (en) *	1991-12-20	1995-11-02	Hoechst Ag	Ethylenic-unsaturated bile acid derivatives, process for their production and preliminary processes therefor
ES2087422T3 (es) *	1991-12-20	1996-07-16	Hoechst Ag	Polimeros y oligomeros de derivados de acidos biliares, procedimiento para su preparacion y su empleo como medicamento.
US5639866A (en) *	1993-02-23	1997-06-17	Princeton University	Single-step formation of multiple glycosidic linkages
IL108748A0 (en) *	1993-02-23	1994-08-26	Univ Princeton	Solution and solid-phase formation of glycosidic linkages
TW289020B (da) *	1993-05-08	1996-10-21	Hoechst Sktiengesellschaft
TW289757B (da) *	1993-05-08	1996-11-01	Hoechst Ag
TW289021B (da) *	1993-05-08	1996-10-21	Hoechst Ag
IT1269839B (it) *	1994-05-26	1997-04-15	Bracco Spa	Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5585470A (en) *	1994-06-23	1996-12-17	Transcell Technologies, Inc.	Process for the manufacture of 3-amino-substituted glycosylated bile acids
US6143864A (en) *	1994-06-28	2000-11-07	Merck & Co., Inc.	Peptides
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) *	1994-09-13	2000-08-22	G.D. Searle And Company	Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en)	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE4432708A1 (de)	1994-09-14	1996-03-21	Hoechst Ag	Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
IL142650A (en) *	1998-04-08	2007-06-03	Galmed Int Ltd	Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
IL123998A (en) *	1998-04-08	2004-09-27	Galmed Int Ltd	Conjugates of bile salts and pharmaceutical preparations containing them
KR20010043558A (ko) *	1998-05-13	2001-05-25	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	감수분열 조절 화합물
IT1304501B1 (it) *	1998-12-23	2001-03-19	Bracco Spa	Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
CN1342090A (zh)	1998-12-23	2002-03-27	G·D·瑟尔有限公司	适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
JP2002533414A (ja)	1998-12-23	2002-10-08	ジー．ディー．サールエルエルシー	心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
EP1340510A1 (en)	1998-12-23	2003-09-03	G.D. Searle LLC.	Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
JP2002533410A (ja)	1998-12-23	2002-10-08	ジー．ディー．サールエルエルシー	心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびフィブリン酸誘導体の組み合わせ
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
US6489366B1 (en)	1998-12-23	2002-12-03	G. D. Searle, Llc	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
PL348508A1 (en)	1998-12-23	2002-05-20	Searle Llc	Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
GB9907048D0 (en) *	1999-03-27	1999-05-19	Karobio Ab	Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
GB2355009A (en) *	1999-07-30	2001-04-11	Univ Glasgow	Peptides conjugated to bile acids/salts
US7413536B1 (en)	1999-09-14	2008-08-19	Xenoport, Inc.	Substrates and screening methods for transport proteins
DE19950686B4 (de) *	1999-10-21	2006-06-29	Martin-Luther-Universität Halle-Wittenberg	Multifunktionelle Spacer
WO2001068637A2 (en)	2000-03-10	2001-09-20	Pharmacia Corporation	Method for the preparation of tetrahydrobenzothiepines
WO2002028881A1 (en) *	2000-10-06	2002-04-11	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002028411A1 (en) *	2000-10-06	2002-04-11	Xenoport, Inc.	Compounds for sustained release of orally delivered drugs
EP1361847A2 (en) *	2000-10-06	2003-11-19	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
US8975246B2 (en)	2001-04-17	2015-03-10	Galmed Research And Development Ltd.	Bile acid or bile salt fatty acid conjugates
US7053076B2 (en) *	2001-08-29	2006-05-30	Xenoport, Inc.	Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
MXPA04003524A (es)	2001-11-02	2004-07-23	Searle Llc	Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
BR0306643A (pt)	2002-01-17	2004-10-19	Pharmacia Corp	Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
JP4611019B2 (ja) *	2002-06-19	2011-01-12	カロバイオエービー	代謝異常治療のための新規な糖質コルチコイド受容体結合体
US7141559B2 (en)	2002-06-19	2006-11-28	Karo Bio Ab	Glucocorticoid receptor ligands for the treatment of metabolic disorders
AU2003293423A1 (en)	2002-12-06	2004-06-30	Xenoport, Inc.	Carbidopa prodrugs and uses thereof
CA2512310C (en) *	2003-01-13	2012-09-25	Bracco Imaging S.P.A.	Improved linkers for radiopharmaceutical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
WO2005066150A1 (en) *	2004-01-02	2005-07-21	Hetero Drugs Limited	A novel process for the preparation of simvastatin
JP4896870B2 (ja) *	2004-04-08	2012-03-14	ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
EP2119455A1 (en) *	2004-04-08	2009-11-18	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Tripartite raftophilic structures and their use
WO2005113008A1 (en) *	2004-05-21	2005-12-01	Mediplex Corp.	Delivery agents for enhancing mucosal absorption of therapeutic agents
US20060003976A1 (en) *	2004-06-04	2006-01-05	Yuehua Zhang	Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
RU2365580C2 (ru)	2004-06-04	2009-08-27	Ксенопорт, Инк.	Пролекарства леводопа, композиции на их основе и их применения
US7323585B2 (en) *	2004-06-04	2008-01-29	Xenoport, Inc.	Levodopa prodrugs, and compositions and uses thereof
TWI403493B (zh)	2005-12-05	2013-08-01	Xenoport Inc	左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
CA2673336A1 (en) *	2006-12-21	2008-06-26	Xenoport, Inc.	Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US7829592B2 (en) *	2006-12-21	2010-11-09	Xenoport, Inc.	Catechol protected levodopa diester prodrugs, compositions, and methods of use
CN101367859B (zh) *	2007-08-17	2011-05-11	中国人民解放军军事医学科学院毒物药物研究所	脂肪酸胆汁酸偶合物及其医药用途
KR101239008B1 (ko) *	2008-03-31	2013-03-04	한양대학교 산학협력단	바일산 유도체 및 그의 응용
KR20110039348A (ko) *	2008-08-06	2011-04-15	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8399513B2 (en) *	2008-10-20	2013-03-19	Xenoport, Inc.	Levodopa prodrug mesylate hydrate
CN102186804A (zh) *	2008-10-20	2011-09-14	克塞诺波特公司	合成左旋多巴酯前药的方法
JP5816097B2 (ja)	2009-01-22	2015-11-18	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
JP6086528B2 (ja)	2009-08-06	2017-03-01	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	長期のインビボ有効性を有する成長ホルモン
WO2011056240A2 (en)	2009-11-09	2011-05-12	Xenoport, Inc.	Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
JP5980689B2 (ja)	2010-01-22	2016-08-31	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
CN118767117A (zh)	2010-01-22	2024-10-15	诺沃—诺迪斯克保健股份有限公司	体内功效延长的生长激素
EP2575821B1 (en)	2010-05-26	2015-08-12	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN104023727B (zh)	2011-10-28	2017-04-05	鲁美纳医药公司	用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2852957C (en)	2011-10-28	2020-08-04	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN105228615A (zh)	2013-03-15	2016-01-06	鲁美纳医药公司	用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
US20140275090A1 (en)	2013-03-15	2014-09-18	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
CN104693264B (zh) *	2015-02-09	2016-09-21	华南理工大学	一种化合物及其制备方法和应用
CN106046101B (zh) *	2016-05-25	2018-01-05	华南理工大学	一种糖原磷酸化酶抑制剂及其制备方法和应用
WO2017210147A1 (en)	2016-05-29	2017-12-07	Wei Jia	Liver disease-related biomarkers and methods of use thereof
CN106496300B (zh) *	2016-10-19	2018-05-18	上海博志研新药物技术有限公司	花生胆酸及其中间体的制备方法
PL3923943T3 (pl)	2019-02-12	2024-12-09	Mirum Pharmaceuticals, Inc.	Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
CN116925168A (zh) *	2019-08-23	2023-10-24	深圳云合医药科技合伙企业(有限合伙)	胆汁酸衍生物及其组合物和应用
US20250002450A1 (en)	2021-12-10	2025-01-02	Universidade Do Porto	Cationic steroid compounds, method of obtaining thereof, formulations comprising thereof and their uses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2441129A (en) *	1942-05-23	1948-05-11	Berczeller Arpad	Bile acid derivatives of aryl sulfonamides
US3937815A (en) *	1975-12-05	1976-02-10	SPA--Societa Prodotti Antibiotici S.p.A.	Lysozyme derivatives
FR2457302A1 (fr) *	1979-05-23	1980-12-19	Roussel Uclaf	Nouveau procede de purification de l'acide ursodesoxycholique
JPS5754151A (en) *	1980-09-18	1982-03-31	Takeda Chem Ind Ltd	Physiologically active substance b-52653 and its preparation
JPS57131735A (en) *	1981-02-09	1982-08-14	Takeda Chem Ind Ltd	Preparation of quinones
US4418059A (en) *	1981-07-20	1983-11-29	Montefiore Medical Center	Nucleoside ester compositions
US4499020A (en) *	1981-07-21	1985-02-12	Montefiore Hospital And Medical Center, Inc.	Mixed anhydrides and processes thereof
FR2511007A1 (fr) *	1981-08-07	1983-02-11	Roussel Uclaf	Procede de preparation de l'acide ursodesoxycholique a partir de l'acide 3a, 7b, 12a-trihydroxycholanique et produit intermediaire utilises
NL8201492A (nl) *	1982-04-07	1983-11-01	Rijksuniversiteit	Werkwijze ter bereiding van een op de 4-plaats equatoriaal gesubstitueerde symmetrisch-polycycloethyleenverbinding; op de 4-plaats equatoriaal gesubstitueerde symmetrisch-polycycloethyleenverbinding alsmede een op basis van de verbinding bereid thermochemiluminescerend merkmateriaal of thermochemiluminescerend sondeermateriaal.
EP0105404A1 (en) *	1982-09-30	1984-04-18	Merck & Co. Inc.	Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation
DE3432094A1 (de) *	1984-08-31	1986-03-06	Hoechst Ag, 6230 Frankfurt	Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
JPS62175497A (ja) *	1986-01-28	1987-08-01	Wakunaga Pharmaceut Co Ltd	胆汁酸誘導体およびその製造法
US5238948A (en) *	1987-02-10	1993-08-24	Hoechst Aktiengesellschaft	Pyridine-2,4- and -2,5-dicarboxylic acid derivatives and medicaments based on these compounds
EP0307342B1 (de) *	1987-07-10	1996-01-03	Hoechst Aktiengesellschaft	3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
US4968790A (en) *	1988-08-12	1990-11-06	American Cyanamid Company	Antidiabetic phosphates
DE3930696A1 (de) *	1989-09-14	1991-03-28	Hoechst Ag	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
DE3931432A1 (de) *	1989-09-21	1991-04-04	Hoechst Ag	Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen

1989
- 1989-09-14 DE DE3930696A patent/DE3930696A1/de not_active Withdrawn
1990
- 1990-09-11 EP EP90117470A patent/EP0417725B1/de not_active Expired - Lifetime
- 1990-09-11 ES ES90117470T patent/ES2100858T3/es not_active Expired - Lifetime
- 1990-09-11 AT AT90117470T patent/ATE152117T1/de not_active IP Right Cessation
- 1990-09-11 DE DE59010706T patent/DE59010706D1/de not_active Expired - Lifetime
- 1990-09-11 DK DK90117470.6T patent/DK0417725T3/da active
- 1990-09-12 FI FI904497A patent/FI105155B/fi active IP Right Grant
- 1990-09-12 IL IL9566890A patent/IL95668A/en unknown
- 1990-09-12 NZ NZ235285A patent/NZ235285A/xx unknown
- 1990-09-13 HU HU905893A patent/HU213395B/hu unknown
- 1990-09-13 PT PT95299A patent/PT95299B/pt not_active IP Right Cessation
- 1990-09-13 ZA ZA907300A patent/ZA907300B/xx unknown
- 1990-09-13 IE IE332990A patent/IE903329A1/en not_active IP Right Cessation
- 1990-09-13 NO NO903999A patent/NO303450B1/no not_active IP Right Cessation
- 1990-09-13 JP JP2241338A patent/JP2568306B2/ja not_active Expired - Lifetime
- 1990-09-13 AU AU62441/90A patent/AU637822B2/en not_active Expired
- 1990-09-13 CA CA002025294A patent/CA2025294C/en not_active Expired - Lifetime
- 1990-09-14 KR KR1019900014542A patent/KR0166962B1/ko not_active Expired - Lifetime
- 1990-09-14 TW TW079107732A patent/TW199097B/zh active
1994
- 1994-03-10 US US08/208,192 patent/US5462933A/en not_active Expired - Lifetime
1995
- 1995-06-07 US US08/476,941 patent/US5646272A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,689 patent/US5668126A/en not_active Expired - Lifetime
- 1995-09-07 JP JP7254511A patent/JP2642089B2/ja not_active Expired - Lifetime
- 1995-09-07 JP JP7254512A patent/JP2642090B2/ja not_active Expired - Lifetime
1997
- 1997-07-15 GR GR970401746T patent/GR3024095T3/el unknown
1998
- 1998-09-29 CY CY9800029A patent/CY2112B1/xx unknown

Also Published As

Publication number	Publication date
JP2568306B2 (ja)	1997-01-08
HU905893D0 (en)	1991-03-28
IL95668A (en)	1995-03-30
US5646272A (en)	1997-07-08
JPH03109396A (ja)	1991-05-09
HUT56115A (en)	1991-07-29
NZ235285A (en)	1993-05-26
NO303450B1 (no)	1998-07-13
ZA907300B (en)	1991-06-26
DE3930696A1 (de)	1991-03-28
HU213395B (en)	1997-06-30
US5668126A (en)	1997-09-16
JPH0892276A (ja)	1996-04-09
CA2025294A1 (en)	1991-03-15
US5462933A (en)	1995-10-31
KR910006319A (ko)	1991-04-29
KR0166962B1 (ko)	1999-01-15
EP0417725A3 (en)	1992-03-18
FI904497A0 (fi)	1990-09-12
PT95299B (pt)	1997-06-30
NO903999L (no)	1991-03-15
EP0417725A2 (de)	1991-03-20
TW199097B (da)	1993-02-01
IL95668A0 (en)	1991-06-30
PT95299A (pt)	1991-05-22
JP2642090B2 (ja)	1997-08-20
JPH0892277A (ja)	1996-04-09
AU6244190A (en)	1991-03-21
DE59010706D1 (de)	1997-05-28
EP0417725B1 (de)	1997-04-23
IE903329A1 (en)	1991-04-10
ES2100858T3 (es)	1997-07-01
ATE152117T1 (de)	1997-05-15
CA2025294C (en)	2001-11-27
NO903999D0 (no)	1990-09-13
AU637822B2 (en)	1993-06-10
JP2642089B2 (ja)	1997-08-20
CY2112B1 (en)	2002-04-26
FI105155B (fi)	2000-06-30
GR3024095T3 (en)	1997-10-31

Publication	Publication Date	Title
DK0417725T3 (da)	1997-11-03	Galdesyrederivater, fremgangsmåder til deres fremstilling samt anvendelse som lægemidler.
DE3887618D1 (de)	1994-03-17	Polyschwefelsäureester von Bis-aldonsäureamiden und deren Derivaten, Verfahren zu ihrer Herstellung und Arzneimittel.
DE69630918D1 (de)	2004-01-15	Matrix für Iontophorese
DK280884A (da)	1984-12-09	Galeniske praeparatformer for orale antidiabetica og fremgangsmaade til deres fremstilling
CS369791A3 (en)	1992-06-17	Bile acids derivatives, process of their preparation and their use as medicament
JPS56166849A (en)	1981-12-22	Method of increasing oral absorption of polarity organism activator
ATE10626T1 (de)	1984-12-15	N-substituierte omega-(2-oxo-imidazolin-1-yl)alkans[uren, deren salze und ester, verfahren zu deren herstellung und diese aktiven substanzen enthaltende pharmazeutische zubereitungen.
ATE59554T1 (de)	1991-01-15	Auf mercaptoethansulfonsaeuren basierende pharmazeutische zusammensetzungen, organische abkoemmlinge von mercaptoethansulfonsaeuren sowie verfahren zu deren herstellung.
ATE111525T1 (de)	1994-09-15	Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
Stimler-Gerard	1986	Immunopharmacology of anaphylatoxin-induced bronchoconstrictor responses
KR900701278A (ko)	1990-12-01	바이러스 감염 치료용 담즙산
NO803918L (no)	1981-06-29	Fremgangsmaate ved fremstilling av nye estere av arginin
ATE89744T1 (de)	1993-06-15	Pharmazeutische zusammensetzung.
DE3884508D1 (de)	1993-11-04	Cystein-derivate mit expectorans-wirkung.
DE3579074D1 (de)	1990-09-13	Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
ES2072904T3 (es)	1995-08-01	Utilizacion de derivados de dextrina para el tratamiento de condiciones acidas.
CN1048157C (zh)	2000-01-12	核糖核酸与肝素复方注射剂
JPS56138115A (en)	1981-10-28	Suppository containing acidic amino acid or derivative thereof
KR890003403A (ko)	1989-04-14	당뇨병의 합병증을 예방하거나 치료하기 위한 제제
JPS5780314A (en)	1982-05-19	Pharmaceutical preparation to be medicated to rectum
Zakharevskiĭ et al.	1976	Biochemical mechanisms of the antihypoxic effect of amichlorphen (diethylaminoethylamide parachlorphenoxyacetic acid)
ATE53384T1 (de)	1990-06-15	3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.
IT1226144B (it)	1990-12-19	Di estere fosforico dell'acido ursodeossicolico e suoi derivati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principi attivi.
JPS6483091A (en)	1989-03-28	Anthracycline derivative active to inhibit reverse transcriptase of human immunodeficiency virus